CHRNA9 and breast cancer: Based on CaMPNets resource (http://campnets.life.nctu.edu.tw), we identify 12 interactions with nicotinic acetylcholine receptor subunit α9 (CHRNA9) across human cancers and validate a use for the Food and Drug Administration (FDA)-approved drug bupropion, which targets CHRNA9, as an anti-metastasis agent in breast cancer.